# US 6,730,667 B2 · Iontophoresis disc pain blocker

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,667 B2
- Document ID: US6730667B2
- Status: Granted
- Kind: B2
- Application number: 09/995,117
- Filed: 2001-11-26
- Published: 2003-05-29
- Granted: 2004-05-04
- Earliest claimed: 2001-11-26
- Inventors: William R. Deagle
- Web page: https://patentgrep.com/patent/US6730667B2

## CPC

- A61N 1/30: Apparatus for iontophoresis, {i.e. transfer of media in ionic state by an electromotoric force into the body}, or cataphoresis
- A61N 1/325: {for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body (electrodes for external use A61N1/0428)}
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)

## Abstract

Treatment of pain syndromes utilizes a topical polypharmaceutical preparation of phenoxybenzamine, ketamine, gabapentin, nifedipine, carbamazepine, or combinations of them. Other suitable components are blockers of sympathetic alpha 1, 2 and other receptors, NMDA receptor blockers, GABA receptor blockers, AMPA receptor blockers, nitric oxide synthase receptor blockers, calcium channel blockers, ACDP receptor blockers, prostaglandin and leukotriene blockers, substance P blockers, bradykinin and neurotenin as well as other peptide blockers, and TNF alpha blockers. Recommended delivery is by locating a predetermined neurodermal point and locating a gel patch over the predetermined neurodermal point. Iontophoresis then delivers the pharmaceutical agent from the gel patch.

## Claims

### Claim 1

A topically effective polypharmaceutical composition consisting essentially of a combination of pharmaceutical agents consisting of an effective dosage of phenoxybenzamine, ketamine, and gabapentin carried in a pluronic lecithin organogel as a topical vehicle, wherein said dosage is a therapeutically effective amount for treating chronic pain by producing a blockade of initiation and propagation of the pain stimulus in the Langerhans and other neuroendocrine vascular structures of the superficial and deep dermis.

### Claim 2 (depends on 1)

The composition of claim 1, wherein said pharmaceutical agents consist of phenoxbenzamine, ketamine, and gabapentin in an approximate quantity ratio of 2:5:5.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the pharmaceutical agents consist of by volume approximately 2% phenoxbenzamine, 5% ketamine, and 5% gabapentin carried in a topical vehicle.

### Claim 4

A method of treating pain by producing a producing a blockade of initiation and propagation of the pain stimulus in the Langerhans and other neuroendocrine vascular structures of the superficial and deep dermis of a humnan or animal subject in need of such treatment, comprising:
performing an administration step by topically administering to the subject in need of such treatment a combination of pharmaceutical agents consisting of an effective dosage of phenoxybenzamine, ketamine, and gabapentin carried in a pluronic lecithin organogel as a topical vehicle.

### Claim 5 (depends on 4)

The method of claim 4, wherein said administration step is performed by topically applying a spray of the said pharmaceutical agents to the subject's skin.

### Claim 6 (depends on 4)

The method of claim 4, wherein said administration step is performed by topically applying a gel cream of the said pharmaceutical agents and topical vehicle to the subject's skin.

### Claim 7 (depends on 4)

The method of claim 4, wherein the said pharmaceutical agents consist of phenoxbenzamine, ketamine, and gabapentin in an approximate quantity ratio of 2:5:5.

### Claim 8 (depends on 4)

The method of claim 4, wherein the said pharmaceutical agents consist of by volume approximately 2% phenoxbenzamine, 5% ketamine, and 5% gabapentin carried in a topical vehicle.
